| Pharmaceutical Information |
| Drug Name |
Procarbazine |
| Drug ID |
BADD_D01846 |
| Description |
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. |
| Indications and Usage |
For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XB01 |
| DrugBank ID |
DB01168
|
| KEGG ID |
D08423
|
| MeSH ID |
D011344
|
| PubChem ID |
4915
|
| TTD Drug ID |
D08GYO
|
| NDC Product Code |
Not Available |
| UNII |
35S93Y190K
|
| Synonyms |
Procarbazine | Procarbazine Monohydrobromide | Monohydrobromide, Procarbazine | Procarbazine Hydrochloride | Hydrochloride, Procarbazine | Procarbazine Monohydrochloride | Monohydrochloride, Procarbazine | Matulane | Natulan |
|
| Chemical Information |
| Molecular Formula |
C12H19N3O |
| CAS Registry Number |
671-16-9 |
| SMILES |
CC(C)NC(=O)C1=CC=C(C=C1)CNNC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
